Current therapeutic approach of chronic kidney disease-mineral and bone disorder.

anti‐osteoporotic agents chronic kidney disease‐mineral and bone disorder (CKD‐MBD) hormonal abnormalities management of electrolytic abnormalities renal osteodystrophy vitamin D administration

Journal

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy

ISSN: 1744-9987

Titre abrégé: Ther Apher Dial

Pays: Australia

ID NLM: 101181252

Informations de publication

Date de publication:
19 Jun 2024

Historique:

revised: 14 05 2024

received: 29 02 2024

accepted: 31 05 2024

medline: 20 6 2024

pubmed: 20 6 2024

entrez: 20 6 2024

Statut: aheadofprint

Résumé

Chronic kidney disease (CKD) has emerged as one of the leading noncommunicable diseases affecting >10% of the population worldwide. Bone and mineral disorders are a common complication among patients with CKD resulting in a poor life quality, high fracture risk, increased morbidity and cardiovascular mortality. According to Kidney Disease: Improving Global Outcomes, renal osteodystrophy refers to changes in bone morphology found in bone biopsy, whereas CKD-mineral and bone disorder (CKD-MBD) defines a complex of disturbances including biochemical and hormonal alterations, disorders of bone and mineral metabolism and extraskeletal calcification. As a result, the management of CKD-MBD should focus on the aforementioned parameters, including the treatment of hyperphosphatemia, hypocalcemia, abnormal PTH and vitamin D levels. Regarding the bone fragility fractures, osteoporosis and renal osteodystrophy, which constitute the bone component of CKD-MBD, anti-osteoporotic agents constitute the mainstay of treatment. However, a thorough elucidation of the CKD-MBD pathogenesis is crucial for the ideal personalized treatment approach. In this paper, we review the pathology and management of CKD-MBD based on the current literature with special attention to recent advances.

Identifiants

DOI: 10.1111/1744-9987.14177 PMID: 38898685

pubmed: 38898685

doi: 10.1111/1744-9987.14177

doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Stephenson Gehman GKHA. Global kidney health atlas 2023 [Internet]; 2023. Available from: www.theisn.org/global-atlas.

Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Cheung M, Jadoul M, et al. Nomenclature for kidney function and disease: executive summary from a KDIGO consensus conference. Nat Rev Nephrol. 2020;16(8):427–428.

Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, et al. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int. 2020;97(6):1117–1129.

Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238–1252.

Chapter 1: definition and classification of CKD. Kidney Int Suppl (2011). 2013;3(1):19–62.

Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945–1953.

Coen G, Ballanti P, Bonucci E, Calabria S, Costantini S, Ferrannini M, et al. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron. 2002;91(1):103–111.

Chapter 1: introduction and definition of CKD–MBD and the development of the guideline statements. Kidney Int. 2009;76:S3–S8.

Iwasaki Y, Kazama JJ, Fukagawa M. Molecular abnormalities underlying bone fragility in chronic kidney disease. Biomed Res Int. 2017;2017:1–11.

Brown EM. Role of the calcium‐sensing receptor in extracellular calcium homeostasis. Best Pract Res Clin Endocrinol Metab. 2013;27(3):333–343.

Rodriguez M, Nemeth E, Martin D. The calcium‐sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol. 2005;288(2):F253–F264.

Goodman WG, Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int. 2008;74(3):276–288.

Vervloet MG, Massy ZA, Brandenburg VM, Mazzaferro S, Cozzolino M, Ureña‐Torres P, et al. Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. Lancet Diabetes Endocrinol. 2014;2(5):427–436.

Goltzman D, Mannstadt M, Marcocci C. Physiology of the calcium‐parathyroid hormone‐vitamin D axis. Front Horm Res. 2018;50:1–13.

Hsu CY, Chen LR, Chen KH. Osteoporosis in patients with chronic kidney diseases: A systemic review. Int J Mol Sci. 2020;21(18):6846.

Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et al. Fibroblast growth factor‐23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16(7):2205–2215.

Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444(7120):770–774.

Hu MC, Kuro‐o M, Moe OW. Klotho and chronic kidney disease. Contrib Nephrol. 2013;180:47–63.

Kuro‐o M. Klotho in chronic kidney disease—what's new? Nephrol Dial Transplant. 2009;24(6):1705–1708.

Hruska KA, Sugatani T, Agapova O, Fang Y. The chronic kidney disease—mineral bone disorder (CKD‐MBD): advances in pathophysiology. Bone. 2017;100:80–86.

Silver J, Rodriguez M, Slatopolsky E. FGF23 and PTH—double agents at the heart of CKD. Nephrol Dial Transplant. 2012;27(5):1715–1720.

Brown EM, Pollak M, Hebert SC. Sensing of extracellular Ca2+ by parathyroid and kidney cells: cloning and characterization of an extracellular Ca(2+)‐sensing receptor. Am J Kidney Dis. 1995;25(3):506–513.

Brown EM, Pollak M, Hebert SC. The extracellular calcium‐sensing receptor: its role in health and disease. Annu Rev Med. 1998;49:15–29.

Llach F, Forero FV. Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney Dis. 2001;38(5):S20–S33.

Portillo MR, Rodríguez‐Ortiz ME. Secondary hyperparthyroidism: pathogenesis, diagnosis, preventive and therapeutic strategies. Rev Endocr Metab Disord. 2017;18(1):79–95.

Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6(4):913–921.

Canalejo R, Canalejo A, Martinez‐Moreno JM, Rodriguez‐Ortiz ME, Estepa JC, Mendoza FJ, et al. FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol. 2010;21(7):1125–1135.

Rodríguez‐Ortiz ME, Rodríguez M. Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease. F1000Research. 2020;9:1077.

Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71(1):31–38. Available from: https://pubmed.ncbi.nlm.nih.gov/17091124/.

Prié D, Friedlander G. Reciprocal control of 1,25‐Dihydroxyvitamin D and FGF23 formation involving the FGF23/klotho system. Clin J Am Soc Nephrol. 2010;5(9):1717–1722.

Haarhaus M, Cianciolo G, Barbuto S, La Manna G, Gasperoni L, Tripepi G, et al. Alkaline phosphatase: an old friend as treatment target for cardiovascular and mineral bone disorders in chronic kidney disease. Nutrients. 2022;14(10):2124.

Nizet A, Cavalier E, Stenvinkel P, Haarhaus M, Magnusson P. Bone alkaline phosphatase: an important biomarker in chronic kidney disease—mineral and bone disorder. Clin Chim Acta. 2020;501:198–206.

Evenepoel P, Cunningham J, Ferrari S, Haarhaus M, Javaid MK, Lafage‐Proust MH, et al. European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4–G5D. Nephrol Dial Transplant. 2021;36(1):42–59.

Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Gutiérrez OM, et al. KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD‐MBD). Am J Kidney Dis. 2017;70(6):737–751.

Millán JL. Alkaline phosphatases: structure, substrate specificity and functional relatedness to other members of a large superfamily of enzymes. Purinergic Signal. 2006;2(2):335–341.

Sardiwal S, Magnusson P, Goldsmith DJA, Lamb EJ. Bone alkaline phosphatase in CKD‐mineral bone disorder. Am J Kidney Dis. 2013;62(4):810–822.

Drechsler C, Verduijn M, Pilz S, Krediet RT, Dekker FW, Wanner C, et al. Bone alkaline phosphatase and mortality in dialysis patients. Clin J Am Soc Nephrol. 2011;6(7):1752–1759.

Bellorin‐Font E, Rojas E, Martin KJ. Bone disease in chronic kidney disease and kidney transplant. Nutrients. 2022;15(1):167.

Sprague SM. Renal bone disease. Curr Opin Endocrinol Diabetes Obes. 2010;17(6):535–539.

Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, et al. The spectrum of bone disease in end‐stage renal failure—an evolving disorder. Kidney Int 1993;43(2):436–442. Available from: https://pubmed.ncbi.nlm.nih.gov/8441240/.

Cheloha RW, Gellman SH, Vilardaga JP, Gardella TJ. PTH receptor‐1 signalling—mechanistic insights and therapeutic prospects. Nat Rev Endocrinol. 2015;11(12):712–724.

Bastepe M, Turan S, He Q. Heterotrimeric G proteins in the control of parathyroid hormone actions. J Mol Endocrinol. 2017;58(4):R203–R224.

Cohen‐Solal ME, Sebert JL, Boudailliez B, Westeel PF, Morinière PH, Marie A, et al. Non‐aluminic adynamic bone disease in non‐dialyzed uremic patients: a new type of osteopathy due to overtreatment? Bone. 1992;13(1):1–5.

Nagy E, Sobh MM, Abdalbary M, Elnagar S, Elrefaey R, Shabaka S, et al. Is adynamic bone always a disease? Lessons from patients with chronic kidney disease. J Clin Med. 2022;11(23):7130.

Massy Z, Drueke T. Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease. J Nephrol. 2017;30(5):629–634.

Hirata J, Hirai K, Asai H, Matsumoto C, Inada M, Miyaura C, et al. Indoxyl sulfate exacerbates low bone turnover induced by parathyroidectomy in young adult rats. Bone. 2015;79:252–258.

Shyu JF, Liu WC, Zheng CM, Fang TC, Hou YC, Chang CT, et al. Toxic effects of indoxyl sulfate on osteoclastogenesis and osteoblastogenesis. Int J Mol Sci. 2021;22(20):11265.

Monier‐Faugere MC, Malluche HH. Role of cytokines in renal osteodystrophy. Curr Opin Nephrol Hypertens. 1997;6(4):327–332.

Nebeker HG, Coburn JW. Aluminum and renal osteodystrophy. Annu Rev Med. 1986;37(1):79–95.

Bover J, Ureña P, Brandenburg V, Goldsmith D, Ruiz C, DaSilva I, et al. Adynamic bone disease: from bone to vessels in chronic kidney disease. Semin Nephrol. 2014;34(6):626–640.

Andress DL. Adynamic bone in patients with chronic kidney disease. Kidney Int 2008;73(12):1345–1354. Available from: https://pubmed.ncbi.nlm.nih.gov/18337716/.

Mucsi I, Hercz G. Relative hypoparathyroidism and adynamic bone disease. Am J Med Sci. 1999;317(6):405. Available from: https://pubmed.ncbi.nlm.nih.gov/10372841/.

Mankin HJ, Mankin CJ. Metabolic bone disease: an update. Instr Course Lect. 2003;52:769–784.

Slatopolsky E, Gonzalez E, Martin K. Proceedings: pathogenesis and treatment of renal osteodystrophy. Blood Purif. 2003;21(4–5):318–326.

Monier‐Faugere MC, Malluche HH. Trends in renal osteodystrophy: a survey from 1983 to 1995 in a total of 2248 patients. Nephrol Dial Transplant. 1996;11(Suppl 3):111–120.

Drüeke TB, Massy ZA. Changing bone patterns with progression of chronic kidney disease. Kidney Int. 2016;89(2):289–302.

Elkhouli E, Nagy E, Santos CGS, Barreto FC, Chaer J, Jorgetti V, et al. Mixed uremic osteodystrophy: an ill‐described common bone pathology in patients with chronic kidney disease. Osteoporos Int. 2023;34(12):2003–2012.

NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7‐29, 2000: highlights of the conference. South Med J. 2001;94(6):569–573.

Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393(10169):364–376.

Bover J, Bailone L, López‐Báez V, Benito S, Ciceri P, Galassi A, et al. Osteoporosis, bone mineral density and CKD–MBD: treatment considerations. J Nephrol. 2017;30(5):677–687.

WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level Summary Meeting Report; 2004.

Ginsberg C, Ix JH. Diagnosis and management of osteoporosis in advanced kidney disease: a review. Am J Kidney Dis. 2022;79(3):427–436.

Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Executive summary of the 2017 KDIGO chronic kidney disease–mineral and bone disorder (CKD‐MBD) guideline update: what's changed and why it matters. Kidney Int. 2017;92(1):26–36.

Pazianas M, Miller PD. Osteoporosis and chronic kidney disease–mineral and bone disorder (CKD‐MBD): back to basics. Am J Kidney Dis. 2021;78(4):582–589.

Desbiens LC, Goupil R, Madore F, Mac‐Way F. Incidence of fractures in middle‐aged individuals with early chronic kidney disease: a population‐based analysis of CARTaGENE. Nephrol Dial Transplant 2020;35(10):1712–1721. Available from: https://pubmed.ncbi.nlm.nih.gov/31951261/.

Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y FGF‐23 in patients with end‐stage renal disease on hemodialysis. Kidney Int 2004;65(5):1943–1946. Available from: https://pubmed.ncbi.nlm.nih.gov/15086938/.

De Seigneux S, Courbebaisse M, Rutkowski JM, Wilhelm‐Bals A, Metzger M, Khodo SN, et al. Proteinuria increases plasma phosphate by altering its tubular handling. J Am Soc Nephrol 2014;26(7):1608–1618. Available from: https://europepmc.org/articles/PMC4483577.

Bover J, Ureña‐Torres P, Cozzolino M, Rodríguez‐García M, Gómez‐Alonso C. The non‐invasive diagnosis of bone disorders in CKD. Calcif Tissue Int. 2021;108(4):512–527. Available from: https://pubmed.ncbi.nlm.nih.gov/33398414/.

Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–1305. Available from: https://pubmed.ncbi.nlm.nih.gov/15385656/.

Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143(11):1157–1172. Available from: https://pubmed.ncbi.nlm.nih.gov/33720773/.

Mafham M, Emberson J, Landray MJ, Wen CP, Baigent C. Estimated glomerular filtration rate and the risk of major vascular events and all‐cause mortality: a meta‐analysis. PLoS One 2011;6(10), e25920. Available from: https://pubmed.ncbi.nlm.nih.gov/22039429/.

Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res. 2011;109(6):697.

Hs YC, Lu CL, Zheng CM, Chen RM, Lin YF, Liu WC, et al. Emerging role of vitamins D and K in modulating uremic vascular calcification: the aspect of passive calcification. Nutrients. 2019;11(1):152.

Kurz P, Monier‐Faugere MC, Bognar B, Werner E, Roth P, Vlachojannis J, Malluche HH Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994;46(3):855–861. Available from: https://pubmed.ncbi.nlm.nih.gov/7996807/.

Reiss AB, Miyawaki N, Moon J, Kasselman LJ, Voloshyna I, D'Avino R, et al. CKD, arterial calcification, atherosclerosis and bone health: inter‐relationships and controversies. Atherosclerosis. 2018;278:49–59.

Morena M, Jaussent I, Dupuy AM, Bargnoux AS, Kuster N, Chenine L, et al. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant 2015;30(8):1345–1356. Available from: https://pubmed.ncbi.nlm.nih.gov/25854266/.

Evenepoel P, D'Haese P, Brandenburg V. Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int 2015;88(2):235–240. Available from: https://pubmed.ncbi.nlm.nih.gov/26083653/.

Mace ML, Gravesen E, Nordholm A, Egstrand S, Morevati M, Nielsen C, et al. Chronic kidney disease‐induced vascular calcification impairs bone metabolism. J Bone Miner Res. 2021;36(3):510–522.

De Mauro D, De Luca G, Marino S, Smakaj A, Rovere G, Liuzza F, et al. Fragility fractures in end‐stage chronic kidney disease (CKD) population: patient‐related and CKD‐related factor analysis—a single‐center experience. J Clin Med. 2024;13(8):2430.

Roshanravan B, Gamboa J, Wilund K. Exercise and CKD: skeletal muscle dysfunction and practical application of exercise to prevent and treat physical impairments in CKD. Am J Kidney Dis. 2017;69(6):837–852.

Gillespie LD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, Clemson LM, et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2012;2012(9):CD007146.

Cupisti A, Gallieni M, Rizzo MA, Caria S, Meola M, Bolasco P. Phosphate control in dialysis. Int J Nephrol Renovasc Dis. 2013;6:193–205. Available from: https://pubmed.ncbi.nlm.nih.gov/24133374/.

Hu L, Napoletano A, Provenzano M, Garofalo C, Bini C, Comai G, la Manna G Mineral bone disorders in kidney disease patients: the ever‐current topic. Int J Mol Sci 2022;23(20), 12223. Available from: https://pubmed.ncbi.nlm.nih.gov/36293076/.

Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, et al. Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD). Cochrane Database Syst Rev. 2018;2018(8):CD006023.

Sprague SM, Martin KJ, Coyne DW. Phosphate balance and CKD–mineral bone disease. Kidney Int Rep. 2021;6(8):2049–2058.

Hill Gallant KM, Spiegel DM. Calcium balance in chronic kidney disease. Curr Osteoporos Rep. 2017;15(3):214–221. Available from: https://pubmed.ncbi.nlm.nih.gov/28474258/.

Wang C, Liu X, Zhou Y, Li S, Chen Y, Wang Y, et al. New conclusions regarding comparison of sevelamer and calcium‐based phosphate binders in coronary‐artery calcification for dialysis patients: a meta‐analysis of randomized controlled trials. PLoS One. 2015;10(7):e0133938.

Palmer SC, Gardner S, Tonelli M, Mavridis D, Johnson DW, Craig JC, et al. Phosphate‐binding agents in adults with CKD: a network meta‐analysis of randomized trials. Am J Kidney Dis. 2016;68(5):691–702.

Barman Balfour JA, Scott LJ. Cinacalcet hydrochloride. Drugs. 2005;65(2):271–281.

Khairallah P, Nickolas TL. Updates in CKD‐associated osteoporosis. Curr Osteoporos Rep. 2018;16(6):712.

Chertow GM, Block GA, Correa‐Rotter R, Drüeke TB, Floege J, Goodman WG, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482–2494.

Parfrey PS, Drüeke TB, Block GA, Correa‐Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Kubo Y, Dehmel B, Goodman WG, Chertow GM, Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators The effects of cinacalcet in older and younger patients on hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Clin J Am Soc Nephrol 2015;10(5):791–799. Available from: https://europepmc.org/articles/PMC4422239.

Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa‐Rotter R, et al. Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial. J Am Soc Nephrol. 2015;26(6):1466–1475.

Behets GJ, Spasovski G, Sterling LR, Goodman WG, Spiegel DM, De Broe ME, et al. Bone histomorphometry before and after long‐term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int. 2015;87(4):846–856. Available from: https://pubmed.ncbi.nlm.nih.gov/25337774/.

Damasiewicz MJ, Ebeling PR. Management of mineral and bone disorders in renal transplant recipients. Nephrology. 2017;22(Suppl 2):65–69. Available from: https://pubmed.ncbi.nlm.nih.gov/28429555/.

Wang AX, Liu S, Montez‐Rath ME, Chertow GM, Lenihan CR. Parathyroidectomy and cinacalcet use in Medicare‐insured kidney transplant recipients. Am J Kidney Dis. 2023;81(3):270–280.e1.

Walter S, Baruch A, Dong J, Tomlinson JE, Alexander ST, Janes J, et al. Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium‐sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J Pharmacol Exp Ther 2013;346(2):229–240. Available from: https://pubmed.ncbi.nlm.nih.gov/23674604/.

Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA 2017;317(2):156–164. Available from: https://pubmed.ncbi.nlm.nih.gov/28097356/.

Karaboyas A, Muenz D, Fuller DS, Desai P, Lin TC, Robinson BM, et al. Etelcalcetide utilization, dosing titration, and chronic kidney disease–mineral and bone disease (CKD‐MBD) marker responses in US hemodialysis patients. Am J Kidney Dis. 2022;79(3):362–373.

Akizawa T, Ikejiri K, Kondo Y, Endo Y, Fukagawa M. Evocalcet: a new oral calcimimetic for dialysis patients with secondary hyperparathyroidism. Ther Apher Dial. 2020;24(3):248–257.

Fukagawa M, Shimazaki R, Akizawa T, Evocalcet study group. Head‐to‐head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 2018;94(4):818–825.

Nagano N, Ishikawa T, Yamaguchi M, Katsuragi Y, Miya M, Tamei N, et al. Long‐term treatment of evocalcet in hemodialysis patients with secondary hyperparathyroidism: a five‐year prospective cohort study in 147 Japanese patients. Ren Replace Ther. 2024;10(1):13.

Hoy SM. Upacicalcet: first approval. Drugs. 2021;81(13):1593–1596.

Shigematsu T, Koiwa F, Isaka Y, Fukagawa M, Hagita K, Watanabe YS, et al. Efficacy and safety of upacicalcet in hemodialysis patients with secondary hyperparathyroidism: a randomized placebo‐controlled trial. Clin J Am Soc Nephrol. 2023;18(10):1300–1309.

Rastogi A, Bhatt N, Rossetti S, Beto J. Management of hyperphosphatemia in end‐stage renal disease: a new paradigm. J Ren Nutr. 2021;31(1):21–34.

Brandenburg V, Ketteler M. Vitamin D and secondary hyperparathyroidism in chronic kidney disease: a critical appraisal of the past, present, and the future. Nutrients. 2022;14(15):3009.

Brandenburg VM, Floege J. Adynamic bone disease‐bone and beyond. NDT Plus. 2008;1(3):135–147.

Komaba H, Zhao J, Karaboyas A, Yamamoto S, Dasgupta I, Hassan M, et al. Active vitamin D use and fractures in hemodialysis patients: results from the international DOPPS. J Bone Miner Res. 2023;38(11):1577–1585.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD‐MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease‐mineral and bone disorder (CKD‐MBD). Kidney Int Suppl. 2009;76(113):S1–S130.

Yeung WCG, Palmer SC, Strippoli GFM, Talbot B, Shah N, Hawley CM, et al. Vitamin D therapy in adults with CKD: a systematic review and meta‐analysis. Am J Kidney Dis. 2023;82(5):543–558.

Lips P, Goldsmith D, de Jongh R. Vitamin D and osteoporosis in chronic kidney disease. J Nephrol. 2017;30(5):671–675.

Jean G, Souberbielle JC, Chazot C. Vitamin D in chronic kidney disease and dialysis patients. Nutrients. 2017;9(4):328.

Coyne DW, Goldberg S, Faber M, Ghossein C, Sprague SM. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3‐4 CKD. Clin J Am Soc Nephrol 2014;9(9):1620–1626. Available from: https://pubmed.ncbi.nlm.nih.gov/24970869/.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD‐MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease‐mineral and bone disorder (CKD‐MBD). Kidney Int Suppl (2011). 2017;7(1):1–59. Available from: https://pubmed.ncbi.nlm.nih.gov/30675420/.

Rodríguez‐Ortiz ME, Pendón‐Ruiz de Mier M V., Rodríguez M. Parathyroidectomy in dialysis patients: indications, methods, and consequences. Semin Dial 2019;32(5):444–451. Available from: https://pubmed.ncbi.nlm.nih.gov/30656752/.

Lau WL, Obi Y, Kalantar‐Zadeh K. Parathyroidectomy in the management of secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2018;13(6):952–961. Available from: https://pubmed.ncbi.nlm.nih.gov/29523679/.

Lu KC, Ma WY, Yu JC, Wu CC, Chu P. Bone turnover markers predict changes in bone mineral density after parathyroidectomy in patients with renal hyperparathyroidism. Clin Endocrinol. 2012;76(5):634–642. Available from: https://pubmed.ncbi.nlm.nih.gov/22007930/.

Ivarsson KM, Akaberi S, Isaksson E, Reihnér E, Czuba T, Prütz KG, et al. Cardiovascular and cerebrovascular events after parathyroidectomy in patients on renal replacement therapy. World J Surg 2019;43(8):1981–1988. Available from: https://pubmed.ncbi.nlm.nih.gov/31087130/.

Chen L, Wang K, Yu S, Lai L, Zhang X, Yuan J, et al. Long‐term mortality after parathyroidectomy among chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta‐analysis. Ren Fail. 2016;38(7):1050–1058. Available from: https://pubmed.ncbi.nlm.nih.gov/27198474/.

Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032–1045.

Swallow EA, Aref MW, Metzger CE, Sacks S, Lehmkuhler DR, Chen N, et al. Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing. Bone. 2019;127:419.

Ott SM. Pharmacology of bisphosphonates in patients with chronic kidney disease. Semin Dial. 2015;28(4):363–369.

Robinson DE, Ali MS, Pallares N, Tebé C, Elhussein L, Abrahamsen B, et al. Safety of oral bisphosphonates in moderate‐to‐severe chronic kidney disease: a binational cohort analysis. J Bone Miner Res. 2021;36(5):820–832.

Vrancken I. Off‐label prescription of medication. Eur J Health Law. 2015;22(2):165–186.

Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015;30(1):3–23. Available from: https://pubmed.ncbi.nlm.nih.gov/25414052/.

Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1–23.

Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011;377(9773):1276–1287. Available from: https://pubmed.ncbi.nlm.nih.gov/21450337/.

Beaudoin C, Jean S, Bessette L, Ste‐Marie LG, Moore L, Brown JP. Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta‐analysis. Osteoporos Int. 2016;27(9):2835–2844.

Jamal SA, Ljunggren Ö, Stehman‐Breen C, Cummings SR, McClung MR, Goemaere S, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 2011;26(8):1829–1835. Available from: https://pubmed.ncbi.nlm.nih.gov/21491487/.

Ominsky MS, Libanati C, Niu QT, Boyce RW, Kostenuik PJ, Wagman RB, et al. Sustained modeling‐based bone formation during adulthood in Cynomolgus monkeys may contribute to continuous BMD gains with denosumab. J Bone Miner Res 2015;30(7):1280–1289. Available from: https://pubmed.ncbi.nlm.nih.gov/25684625/.

Samelson EJ, Miller PD, Christiansen C, Daizadeh NS, Grazette L, Anthony MS, et al. RANKL inhibition with denosumab does not influence 3‐year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. J Bone Miner Res. 2014;29(2):450–457. Available from: https://pubmed.ncbi.nlm.nih.gov/23873632/.

Dave V, Chiang CY, Booth J, Mount PF. Hypocalcemia post denosumab in patients with chronic kidney disease stage 4‐5. Am J Nephrol. 2015;41(2):129–137.

Bird ST, Smith ER, Gelperin K, Jung TH, Thompson A, Kambhampati R, et al. Severe hypocalcemia with denosumab among older female dialysis‐dependent patients. JAMA. 2024;331(6):491–499.

Khan A, Morrison A, Cheung A, Hashem W, Compston J. Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015. Osteoporos Int. 2016;27(3):853–859. Available from: https://pubmed.ncbi.nlm.nih.gov/26493811/.

Fassio A, Adami G, Benini C, Vantaggiato E, Saag KG, Giollo A, et al. Changes in Dkk‐1, sclerostin, and RANKL serum levels following discontinuation of long‐term denosumab treatment in postmenopausal women. Bone. 2019;123:191–195.

Kim AS, Girgis CM, McDonald MM. Osteoclast recycling and the rebound phenomenon following denosumab discontinuation. Curr Osteoporos Rep. 2022;20(6):505–515.

Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JEB, McClung M, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo‐controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33(2):190–198.

Black DM, Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2016;374(3):254–262.

Anantharaman P, Schmidt RJ. Sexual function in chronic kidney disease. Adv Chronic Kidney Dis. 2007;14(2):119–125.

Mosca L, Grady D, Barrett‐Connor E, Collins P, Wenger N, Abramson BL, et al. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke 2009;40(1):147–155. Available from: https://pubmed.ncbi.nlm.nih.gov/18948611/.

Haghverdi F, Farbodara T, Mortaji S, Soltani P, Saidi N. Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5. Iran J Kidney Dis. 2014;8(6):461–466.

Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol. 2008;19(7):1430–1438.

Hernández E, Valera R, Alonzo E, Bajares‐Lilue M, Carlini R, Capriles F, et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int. 2003;63(6):2269–2274.

Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, et al. Effects of teriparatide [recombinant human parathyroid hormone (1–34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res. 2003;18(3):539–543. Available from: https://pubmed.ncbi.nlm.nih.gov/12619939/.

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–1441. Available from: https://pubmed.ncbi.nlm.nih.gov/11346808/.

Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int. 2007;18(1):59–68.

Nishikawa A, Yoshiki F, Taketsuna M, Kajimoto K, Enomoto H. Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study. Clin Interv Aging. 2016;11:1653–1659. Available from: https://pubmed.ncbi.nlm.nih.gov/27895472/.

Evenepoel P, Bover J, Ureña Torres P. Parathyroid hormone metabolism and signaling in health and chronic kidney disease. Kidney Int 2016;90(6):1184–1190. Available from: https://pubmed.ncbi.nlm.nih.gov/27653840/.

Ota M, Takahata M, Shimizu T, Kanehira Y, Kimura‐Suda H, Kameda Y, et al. Efficacy and safety of osteoporosis medications in a rat model of late‐stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia. Osteoporos Int. 2017;28(4):1481–1490.

Seeman E, Martin TJ. Antiresorptive and anabolic agents in the prevention and reversal of bone fragility. Nat Rev Rheumatol. 2019;15(4):225–236. Available from: https://pubmed.ncbi.nlm.nih.gov/30755735/.

Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ. Binding selectivity of abaloparatide for PTH‐Type‐1‐receptor conformations and effects on downstream signaling. Endocrinology 2016;157(1):141–149. Available from: https://pubmed.ncbi.nlm.nih.gov/26562265/.

Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 2016;316(7):722–733. Available from: https://pubmed.ncbi.nlm.nih.gov/27533157/.

Baron R, Rawadi G. Targeting the Wnt/beta‐catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148(6):2635–2643.

Evenepoel P, Opdebeeck B, David K, D'Haese PC. Bone‐vascular axis in chronic kidney disease. Adv Chronic Kidney Dis. 2019;26(6):472–483. Available from: https://pubmed.ncbi.nlm.nih.gov/31831125/.

Moe SM, Chen NX, Newman CL, Organ JM, Kneissel M, Kramer I, et al. Anti‐sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. J Bone Miner Res. 2015;30(3):499–509.

Bonnet N, Conway SJ, Ferrari SL. Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin. Proc Natl Acad Sci U S A. 2012;109(37):15048–15053. Available from: https://pubmed.ncbi.nlm.nih.gov/22927401/.

McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez‐Perez A, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):248–259. Available from: https://pubmed.ncbi.nlm.nih.gov/24382002/.

Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417–1427. Available from: https://pubmed.ncbi.nlm.nih.gov/28892457/.

Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532–1543. Available from: https://pubmed.ncbi.nlm.nih.gov/27641143/.

Lewiecki EM, Dinavahi R V., Lazaretti‐Castro M, Ebeling PR, Adachi JD, Miyauchi A, et al. One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J Bone Miner Res. 2019;34(3):419–428. Available from: https://pubmed.ncbi.nlm.nih.gov/30508316/.

Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open‐label, phase 3 trial. Lancet 2017;390(10102):1585–1594. Available from: https://pubmed.ncbi.nlm.nih.gov/28755782/.

De Maré A, Opdebeeck B, Neven E, D'Haese PC, Verhulst A. Sclerostin protects against vascular calcification development in mice. J Bone Miner Res. 2022;37(4):687–699.

Brandenburg VM, Verhulst A, Babler A, D'Haese PC, Evenepoel P, Kaesler N. Sclerostin in chronic kidney disease‐mineral bone disorder think first before you block it! Nephrol Dial Transplant. 2019;34(3):408–414. Available from: https://pubmed.ncbi.nlm.nih.gov/29846712/.

Towler DA. Commonalities between vasculature and bone: an osseocentric view of arteriosclerosis. Circulation. 2017;135(4):320–322.

Miller PD, Adachi JD, Albergaria B, Cheung AM, Chines AA, Gielen E, et al. Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild‐to‐moderate chronic kidney disease. J Bone Miner Res. 2022;37(8):1437–1445.

Malluche HH, Faugère MC, Ritz E, Caillens G, Wildberger D. Endogenous calcitonin does not protect against hyperparathyroid bone disease in renal failure. Miner Electrolyte Metab. 1986;12(2):113–118.

Hou YC, Lu CL, Lu KC. Mineral bone disorders in chronic kidney disease. Nephrology. 2018;23(S4):88–94.